In the vast and often indiscriminate terrain of cancer biology, precision medicine advances by learning to distinguish the rare from the common — and to act on that distinction. Researchers at SUNY Upstate Medical University have mapped the occurrence of a specific genetic mutation, KRAS G12C, across more than thirteen thousand genitourinary tumor specimens, finding it present in only 25 cases, yet concentrated meaningfully in bladder cancer. The significance lies not in the numbers alone, but in what they represent: a narrow molecular doorway, now visible, through which targeted therapies alr